Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 3/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.37 |
| ▸ | BMP1 | P13497 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20137037 | 0.90 | KDM4E (0.38) | RXRANR1H2NR1H3MAPTPOLB | |
| SCHEMBL20137115 | 0.89 | LTB4R2 (0.44) | LTB4R2CSNK1DBMP1BCHECNR2 | |
| Hydrochloric Acid SCHEMBL20137043 | 0.89 | KDM4E (0.37) | RXRANR1H2NR1H3MAPTPOLB | |
| SCHEMBL20570505 | 0.89 | LTB4R2 (0.42) | LTB4R2CSNK1DRXRANR1H2BMP1 | |
| SCHEMBL20150068 | 0.88 | TSPO (0.39) | NR1D1BCHEPOLB | |
| SCHEMBL20137127 | 0.88 | BMP1 (0.37) | LTB4R2CSNK1DBMP1NR1D1SLC2A1 | |
| SCHEMBL20137405 | 0.87 | BCL2A1 (0.38) | NR1D1BCHE | |
| SCHEMBL20182405 | 0.82 | LTB4R2 (0.42) | LTB4R2RXRANR1H2BMP1NR1H3 | |
| SCHEMBL29531297 | 0.79 | MGLL (0.47) | RXRANR1H2MAPT | |
| SCHEMBL20137009 | 0.78 | MGLL (0.36) | RXRANR1H2NR1H3MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3634404-B1 | PYRAZOLE MAGL INHIBITORS | H LUNDBECK AS (DK) | 2024-11-20 | — | — | EP | disclosed |
| EP-3541820-B1 | MAGL INHIBITORS | H LUNDBECK AS (DK) | 2023-07-05 | — | — | EP | disclosed |
| EP-3541820-B1 | MAGL INHIBITORS | H LUNDBECK AS (DK) | 2023-07-05 | — | — | EP | disclosed |
| US-11691975-B2 | MAGL inhibitors | H. LUNDBECKA/S (DK) | 2023-07-04 | — | — | US | disclosed |
| US-11691975-B2 | MAGL inhibitors | H. LUNDBECKA/S (DK) | 2023-07-04 | — | — | US | disclosed |
| US-20220135563-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2022-05-05 | — | — | US | disclosed |
| US-20220135563-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2022-05-05 | — | — | US | disclosed |
| EP-3541822-B1 | MAGL INHIBITORS | H LUNDBECK AS (DK) | 2022-01-19 | — | — | EP | disclosed |
| EP-3541822-B1 | MAGL INHIBITORS | H LUNDBECK AS (DK) | 2022-01-19 | — | — | EP | disclosed |
| US-11149037-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2021-10-19 | — | — | US | disclosed |
| US-20200087304-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2020-03-19 | — | — | US | disclosed |
| EP-3541820-A1 | MAGL INHIBITORS | Abide Therapeutics, Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| EP-3541822-A1 | MAGL INHIBITORS | Abide Therapeutics, Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018217809-A1 | PYRAZOLE MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-11-29 | — | — | WO | disclosed |
| US-9981930-B1 | MAGL inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| WO-2018093949-A1 | MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018093949-A1 | MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018093946-A1 | MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018093946-A1 | MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| US-20180134675-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135563-A1 | MAGL INHIBITORS | MAG, MAGI3, MGLL | LTB4R2 2100/4885CSNK1D 2430/4885RXRA 2778/4885 |
| US-11149037-B2 | Pyrazole MAGL inhibitors | MAGI3, MAG, PYM1 | LTB4R2 1060/4885CSNK1D 2300/4885RXRA 3312/4885 |
| US-20200087304-A1 | PYRAZOLE MAGL INHIBITORS | MAGI3, MAG, PYM1 | LTB4R2 1060/4885CSNK1D 2300/4885RXRA 3312/4885 |
| US-11691975-B2 | MAGL inhibitors | MAG, MAGI3, MGLL | LTB4R2 2100/4885CSNK1D 2430/4885RXRA 2778/4885 |
| US-20180134675-A1 | MAGL INHIBITORS | MAG, MAGI3, MGLL | LTB4R2 1924/4885CSNK1D 2554/4885RXRA 3591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.